Traditional drug discovery methods are expensive and time-intensive for pharmaceutical companies. Adimab Co-Founder & CEO Tillman Gerngross and Anthony Lacavera discuss how the platform reduces the barriers to drug development.
Traditional drug discovery methods are expensive and time-intensive for pharmaceutical companies. Adimab Co-Founder & CEO Tillman Gerngross and Anthony Lacavera discuss how the platform reduces the barriers to drug development.